期刊文献+

Graves病患者外周血FOXP3、GITR及CD25基因的表达

Expression of FOXP3,GITR and CD25 genes in peripheral blood of patients with Graves' disease
原文传递
导出
摘要 目的研究Graves病(GD)不同阶段患者外周血叉状头/翅膀状螺旋转录因子(FOXP3)、糖皮质激素诱导肿瘤坏死因子受体(GITR)及IL-2受体α链(CD25)基因的表达变化,探讨其在GD发病机制中的作用。方法收集GD患者90例,按病情分为GD初诊组30例(男13例,女17例);GD缓解组30例(男10例,女20例);GD复发组30例(男11例,女19例)。健康查体者30例(男14例,女16例)作为健康对照组。应用实时荧光定量PCR法检测各组外周血单个核细胞中FOXP3、GITR及CD25mRNA含量,同时利用电化学发光的方法测定各组血清甲状腺激素水平及甲状腺过氧化酶抗体(TPOAb)、甲状腺球蛋白抗体(TGAb)的水平。结果GD各组患者外周血FOXP3mRNA表达均较健康对照组显著降低(P<0.05),GD缓解组FOXP3mRNA水平较GD初诊组显著升高(P<0.05),复发组FOXP3mRNA水平虽低于缓解组(P<0.05),但明显高于GD初诊组(P<0.05);GD各组女性患者FOXP3mRNA表达水平显著高于男性患者(P<0.05);Graves初诊及复发组GITRmRNA、CD25mRNA表达水平显著高于对照组(P<0.05)。结论FOXP3、GITR及CD35可能参与了Graves的发生、发展及复发过程。 Objective To investigate the roles of FOXP3,GITR and CD25 genes in the pathogenesis of different stages of ulcerative Graves' disease.Methods Ninety patients with Graves' disease were averagely divided into three groups:the newly diagnosed group(13 males,17 females),the remission group(10 males,20 females)and the recurrence group(11 males,19 females).Thirty normal persons(14 males,16 females)served as healthy controls.The levels of FOXP3,GITR and CD25mRNA in peripheral blood mononuclear cells were measured by the Light Cycler fluorescence quantitative PCR instrument,and the levels of serum thyroid hormone,TPOAb and TGAb were measured by electrochemiluminescence.Results The level of FOXP3 mRNA in each Graves' disease group was significantly lower than in the healthy controls(P〈0.05),the FOXP3 mRNA level in the remission group was significantly higher than in the newly diagnosed group(P〈0.05),and the FOXP3 mRNA level in the recurrence group was lower than in the remission group(P〈0.05)but higher than in the newly diagnosed group(P〈0.05).The level of FOXP3 mRNA in female GD patients was significantly higher than in male GD patients(P〈0.05).The levels of GITR mRNA and CD25 mRNA in the newly diagnosed and recurrence groups increased compared with that in the healthy controls(P〈0.05).Conclusion The FOXP3,GITR and CD25 genes may be involved in the process of Graves' disease and its recurrence.
出处 《山东大学学报(医学版)》 CAS 北大核心 2009年第12期1-5,共5页 Journal of Shandong University:Health Sciences
基金 山东省自然科学基金资助课题(2009ZRB1416)
关键词 GRAVES病 CD4^+CD25^+调节性T细胞 叉状头/翅膀状螺旋转录因子 Graves’ disease CD4^+/CD25^+ regulatory T cells Forkhead box protein 3
  • 相关文献

参考文献12

  • 1Onmesu E, Bagnasco M, Salmaso C, et al. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal[J]. Eur J of Clin Invest, 2004, 34 (3) :210-217.
  • 2Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3 [ J ]. Science,2003, 299(5609) : 1057-1061.
  • 3中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:835
  • 4Contasta I, Pellegrini P, Berghella A M, et al. Cell cycle control in cellular homeostasis during the immune response: interactions between TH1, TH2 cytokines, and Bcl2 and p53 molecules[J]. Cancer Biother Radiopharm, 2001, 16(1) :63-71.
  • 5Wang H, Zhao S, Tang X, et al. Changes of regulatory T cells in Graves' disease[J]. Huazhong Univ Sci Technolog Med Sci, 2006, 26(5) :545-547.
  • 6唐大海,徐尔理,吴玲.Graves病患者外周血CD4^+、CD25^+调节性T细胞的定量及功能分析[J].海军医学杂志,2008,29(2):114-118. 被引量:14
  • 7Morgan M E, van Bilsen J H, Bakker A M, et al. Expression of FOXP3 mRNA is not confined to CD4^+ CD25^+ T regulatory cells in humans[J]. Hum Immunol, 2005, 66(1):13-20.
  • 8Polanczyk M J, Carson B D, Subramanian S, et al. Cutting edge: estrogen drives expansion of the CD4^+ CD25^+ regulatory T cell compartment [ J ]. J Immunol, 2004, 173 (4) : 2227- 2230.
  • 9王深明,毛盛明,赵国强,吴惠茜.雌激素受体与Graves病的相关性[J].中华外科杂志,2000,38(8):619-621. 被引量:5
  • 10Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25( + ) CD4( + ) regulatory T cells through GITR breaks immunological serf-tolerance[J]. Nat Immunol, 2002, 3(2): 135-142.

二级参考文献21

  • 1白耀.甲状腺病学-基础与临床[M].北京:科学技术文献出版社,2004.388.
  • 2Davies TF, Larsen PR. Thyrotixicosis// Larsen PR, Kronenberg HM, Melmed S. Wlilliams textbook of endocrinology. 10th ed. Philadelphia: Saunders, 2002: 374-424.
  • 3Chiovato L, Babesino G, Pinchera A. Graves disease//DeGroot LJ, Jameson JL. Endocrinology. 4th ed. Philadelphia: Saunders, 2001 : 1422-1449.
  • 4Greenspan FS. The thyroid gland//Greenspan FS, Gardner DG. Basic and clinical endocrinology. New York: Lange /McGraw- Hill, 2001: 201-272.
  • 5Fisher DA. Disorders of the thyroid in the newborn and infant// Sperling MA. Pediatric endocrinology. 2nd ed. Philadelphia: Sannders, 2002 : 161-186.
  • 6Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med, 2000, 160:1573-1575.
  • 7American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract, 2002,8:457-469.
  • 8Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006, 354:2783-2793.
  • 9Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid, 2003,13 : 3-126.
  • 10Cooper DS. Antithyroid drugs. N Engl J Med, 2005, 352:905- 917.

共引文献850

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部